Abstract
The natural stilbenoids combretastatin A-4 (CA4) and combretastatin A-1 (CA1) are potent antitubulin agents demonstrating antimitotic activity as well as tumor vascular disruption property. Due to structural simplicity and potent cytotoxicity of CA4 and CA1, they are considered as promising leads for the development of potent anticancer agents. In fact, scientific fraternity is motivated to synthesize several derivatives of CA4 and CA1 as novel therapeutic agents. In the literature, several studies have been carried out to evaluate the medicinal chemistry, pharmacology and structure–activity relationships (SAR) of a variety of modified combretastatin derivatives. The present report aimed at comprehensively revising the recent advancements (2006-2014) in the medicinal chemistry and SAR of diversified combretastatin analogues. The published data concerning new combretastatin A-4 analogues as antimitotic anticancer agents are presented and SAR is reviewed and discussed.
Keywords: Anticancer, antineoplastic, combretastatin, combretastatin analogues, cytotoxicity, natural products, SAR, tubulin inhibitors, vascular disrupting agent.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Recent Advancement in Discovery and Development of Natural Product Combretastatin-inspired Anticancer Agents
Volume: 15 Issue: 8
Author(s): Pravin O. Patil, Ashwini G. Patil, Rajesh A. Rane, Pravin C. Patil, Prashant K. Deshmukh, Sanjay B. Bari, Dilip A. Patil and Shital S. Naphade
Affiliation:
Keywords: Anticancer, antineoplastic, combretastatin, combretastatin analogues, cytotoxicity, natural products, SAR, tubulin inhibitors, vascular disrupting agent.
Abstract: The natural stilbenoids combretastatin A-4 (CA4) and combretastatin A-1 (CA1) are potent antitubulin agents demonstrating antimitotic activity as well as tumor vascular disruption property. Due to structural simplicity and potent cytotoxicity of CA4 and CA1, they are considered as promising leads for the development of potent anticancer agents. In fact, scientific fraternity is motivated to synthesize several derivatives of CA4 and CA1 as novel therapeutic agents. In the literature, several studies have been carried out to evaluate the medicinal chemistry, pharmacology and structure–activity relationships (SAR) of a variety of modified combretastatin derivatives. The present report aimed at comprehensively revising the recent advancements (2006-2014) in the medicinal chemistry and SAR of diversified combretastatin analogues. The published data concerning new combretastatin A-4 analogues as antimitotic anticancer agents are presented and SAR is reviewed and discussed.
Export Options
About this article
Cite this article as:
O. Patil Pravin, G. Patil Ashwini, A. Rane Rajesh, C. Patil Pravin, K. Deshmukh Prashant, B. Bari Sanjay, A. Patil Dilip and S. Naphade Shital, Recent Advancement in Discovery and Development of Natural Product Combretastatin-inspired Anticancer Agents, Anti-Cancer Agents in Medicinal Chemistry 2015; 15 (8) . https://dx.doi.org/10.2174/1871520615666150526141259
DOI https://dx.doi.org/10.2174/1871520615666150526141259 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
FDG-PET Scan in Sarcoidosis: Clinical and Imaging Indications
Current Medical Imaging Synthesis and Evaluation of 99mTc Chelate-conjugated Bevacizumab
Current Radiopharmaceuticals A Compendium of Volatile Organic Compounds (VOCs) Released By Human Cell Lines
Current Medicinal Chemistry Development of Peptides as Potential Drugs for Cancer Therapy
Current Pharmaceutical Design Opportunities to Improve the Prevention and Treatment of Cervical Cancer
Current Molecular Medicine Complications of Paget Bone Disease: A Study of 69 Patients
Current Rheumatology Reviews RNA Interference: A New Targeted Tumour Therapy?
Current Cancer Therapy Reviews Boron-Containing Compounds as Preventive and Chemotherapeutic Agents for Cancer
Anti-Cancer Agents in Medicinal Chemistry CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review
Protein & Peptide Letters Shutting Down the Furnace: Preferential Killing of Cancer Cells with Mitochondrial-Targeting Molecules
Current Medicinal Chemistry Target Fishing of Calactin, Calotropin and Calotoxin Using Reverse Pharmacophore Screening and Consensus Inverse Docking Approach
Current Drug Discovery Technologies miRNA and Proteomic Dysregulation in Non-Small Cell Lung Cancer in Response to Cigarette Smoke
MicroRNA Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) MicroRNA and Bone Tumor: To Up Date
Current Signal Transduction Therapy Identification of KEY lncRNAs and mRNAs Associated with Oral Squamous Cell Carcinoma Progression
Current Bioinformatics Advances in the Development of Virus-Like Particles as Tools in Medicine and Nanoscience
Current Chemical Biology A Narrative Review of Diabetes Group Visits in Low-Income and Underserved Settings
Current Diabetes Reviews Naturally-occurring Dimers of Flavonoids as Anticarcinogens
Anti-Cancer Agents in Medicinal Chemistry Advances in Electrospinning of Nanofibers and their Biomedical Applications
Current Tissue Engineering (Discontinued) Induction of Senescent-Like Growth Arrest as a New Target in Anticancer Treatment
Current Cancer Drug Targets